It was reported that, on (b)(6) 2024, a patient began therapy with sq remodulin to treat a primary pulmonary arterial hypertension.On an unknown date in feb-2024, the patient was hospitalized for two weeks due to a subcutaneous infection (cellulitis at the infusion site) and patient though she was allergic to opsite iv 3000 (dermatitis contact).Since then, she had not been handling the site pain (infusion site pain) and wanted to come off the remodulin.At the time of reporting, the outcome of infusion site cellulitis and dermatitis contact was unknown, and the outcome of infusion site pain was not resolved.No further information is available.
|